1. Home
  2. TILE vs NTLA Comparison

TILE vs NTLA Comparison

Compare TILE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interface Inc.

TILE

Interface Inc.

N/A

Current Price

$37.42

Market Cap

2.2B

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$12.71

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TILE
NTLA
Founded
1973
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
TILE
NTLA
Price
$37.42
$12.71
Analyst Decision
Buy
Buy
Analyst Count
1
23
Target Price
$36.00
$20.02
AVG Volume (30 Days)
477.4K
3.3M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
0.29%
N/A
EPS Growth
32.43
27.43
EPS
1.28
N/A
Revenue
$1,386,854,000.00
$67,671,000.00
Revenue This Year
$6.72
N/A
Revenue Next Year
$5.61
$62.75
P/E Ratio
$28.91
N/A
Revenue Growth
5.41
16.92
52 Week Low
$24.40
$7.95
52 Week High
$40.50
$28.24

Technical Indicators

Market Signals
Indicator
TILE
NTLA
Relative Strength Index (RSI) 49.56 55.01
Support Level $27.29 $11.55
Resistance Level $40.07 $13.88
Average True Range (ATR) 1.08 0.63
MACD -0.36 0.10
Stochastic Oscillator 11.91 69.18

Price Performance

Historical Comparison
TILE
NTLA

About TILE Interface Inc.

Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: